#WorldDiabetesDay aims to raise awareness about the condition and help combat the increasing rates of #diabetes across the world. Let’s join hands to support healthy living to curb this morbid disease!

Image Posted on Updated on




Posted on

USFDA warns Bengaluru-based Resonance Labs of manufacturing norms violations

Vitamin B3 prevents glaucoma according to researchers in US.

Zydus Cadila receives USFDA nod to market fluconazole tablets

U.S. experts soften on DNA editing of human eggs, sperm, embryos

Source: Notizia

Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation

Posted on

Familial Adenomatous Polyposis (FAP) results from a germ line mutation in the Adenomatous Polyposis Coli (APC) gene. FAP is an autosomal dominantly inherited disorder, which is characterized by the formation of numerous colorectal adenomatous polyps and leads to the cancer of the large intestine.

Source: Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation

Clinical Trials need to assess drug efficacy before first-in-human trials

Posted on Updated on

On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France. Four of five other subjects receiving the same dose have serious, ongoing neurological complications. Investigations into the trial described many troubling safety practices, such as steep increases in dose levels delivered to sequential subjects without sufficient delays to check for safety. In the wake of the tragedies, the French medicines safety agency (ANSM) ordered an examination of the information that the drug developer, Bial, based in Trofa, Portugal, had supplied to ethics committees and potential researchers before the trial. The report notes that the 63-page Investigator Brochure describing the trial included fewer than two pages of evidence that the drug had the desired pharmacological activity. It identified only two studies presented as evidence for efficacy, both problematic. A lack of emphasis on evidence for the efficacy of drug candidates is all too common in decisions about whether an experimental medicine can be tested in humans. There is a need to call for infrastructure, resources and better methods to rigorously evaluate the clinical promise of new interventions before testing them on humans for the first time, to ensure safety from bogus medicines.

To know more, click here

Chronic Obstructive Pulmonary Disorder

Posted on

To understand COPD and know about it, please click INFOGRAPHIC_6thFEB.

Source: Chronic Obstructive Pulmonary Disorder